Getting Innovations to Patients During Shutdowns Act
To amend the Federal Food, Drug, and Cosmetic Act to establish special rules to provide for continued review of human drug and device submissions during a lapse of appropriations, and for other purposes.
This bill, HB9635, aims to update the Federal Food, Drug, and Cosmetic Act by creating special rules. These rules would ensure that the review process for human drug and device submissions can continue even if there is a gap in government funding. This means that important medical reviews would not be delayed due to budget issues.
The bill would mainly affect the agencies responsible for reviewing drugs and medical devices, such as the FDA, as well as the companies and individuals submitting these products for approval. By establishing a plan for continued review during funding lapses, the bill seeks to protect public health and maintain the efficiency of the approval process.
HB9635 was introduced on July 9, 2026, and has been referred to the House Committee on Energy and Commerce for further review. This is the first step in the legislative process, and the committee will evaluate the bill's details and potential impact before deciding on the next steps.
